$ARE

Alexandria Real Estate Equities Stock: Is ARE Underperforming the Real Estate Sector?

Alexandria Real Estate Equities (ARE), a mid-cap life science REIT, reported Q2 2026 adjusted FFO of $1.73 per share, beating estimates, but revenue fell 13% YoY to $662.78M. ARE stock is up 14.3% YTD but down 34.3% over 52 weeks, underperforming the XLRE ETF. Analysts have a 'Hold' consensus rating with a mean price target of $53.

Original reporting
Published Sep 18, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alexandria Real Estate Equities Stock: Is ARE Underperforming the Real Estate Sector? — source image
Decision brief

The 30-second read

$AREBearishMed
01

Why it matters

Earnings miss and narrowed guidance suggest near‑term earnings pressure, likely weighing on the stock and sector.

02

Market read

ARE's earnings shortfall may trigger sector‑wide reassessment of life‑science REIT valuations.

03

What to watch

Potential upside from upcoming capital transactions and delayed dispositions could improve cash flow later in the year.

Relevance 8/10Novelty 8/10Timing: post‑earnings day, shares tumbled next day

Background

ARE is a mid‑cap life‑science REIT with a $9.3 B market cap; Q2 results showed revenue and rental income declines.

Company-level read

Ticker impact

$AREBearishMedium confidence
Context

Q2 2026 adjusted FFO of $1.73 per share reported; revenue down 13% YoY; guidance narrowed to $6.35‑$6.45 per share; stock fell 7.8% after release.

Expected impact

Potential further decline of 3‑5% over the next week if guidance holds.

Evidence & confidence

Revenue and rental income fell sharply; guidance below consensus; market reaction already negative.

Market effects

Life‑science REIT sector may see pressure as peers' earnings underperform.

U.S. REIT market could see modest pullback amid weaker real‑estate income data.

Limited to U.S. REIT investors; no broader macro effect.

Counterpoint

If the market overreacts, the dip could present a buying opportunity at a discount.

Key entities

  • Alexandria Real Estate Equities, Inc.

    Life‑science REIT reporting Q2 2026 results.

Related articles

$AREMed

Alexandria Real Estate Equities spared from class action suit

A judge dismissed a class action lawsuit against Alexandria Real Estate Equities, alleging false statements about a Queens property. The case was dismissed without prejudice. Alexandria's stock is down 38% over the past year, trading at $52.82. The company faces potential $183M preconstruction cost issues for a Manhattan project.

$AREHighAI 8/10

Alexandria’s (ARE) Profit Rebound Comes With A Cash Flow Catch

Alexandria Real Estate Equities (ARE) reported a narrower Q2 2026 net loss of $0.43 per share, but FFO per share declined. Leasing activity improved, with 1.04 million sq. ft. signed, and occupancy reached 90.9%. The company has $3.6B in liquidity and extended its credit line. However, same-property NOI fell 10.6%, and rental rates declined. Net debt to EBITDA is 7.0x, above target.

$AREMedAI 8/10

Does Alexandria Real Estate Equities' (ARE) $1 Billion Subordinated Note Deal Reframe Its Risk-Reward Profile?

Alexandria Real Estate Equities (ARE) completed a $1B subordinated, unsecured note offering due 2057, with a variable coupon and institutional support. The deal adds long-term funding but doesn't alter near-term risks like vacancies and capital markets uncertainty. ARE projects $2.7B revenue and $479.3M earnings by 2029, with analysts' estimates varying slightly.